The phase III IMbrave150 study evaluating Tecentriq in combination with Avastin in people with unresectable hepatocellular carcinoma met its co-primary endpoints of overall survival and progression-free survival, compared with standard-of-care sorafenib.
Over the past three years, the American Cancer Society has recovered from the fundraising decline brought on by COVID-19 and has reversed the years-long fundraising slump in public support.
